Champions Oncology (CSBR) Cash from Investing Activities (2010 - 2026)
Champions Oncology (CSBR) posted quarterly Cash from Investing Activities of -$238000.0 for Q2 2026, up 5.93% year-over-year from -$224679.1 in Q2 2025, and down 1600.0% quarter-over-quarter from -$14000.0 in Q1 2026.
Champions Oncology (CSBR) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Champions Oncology's Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$238000.0 for Q2 2026.
- In Q2 2026, Cash from Investing Activities rose 5.93% year-over-year to -$238000.0; the TTM figure through Apr 2026 stood at -$540000.0 (down 38.82% YoY), while the FY2026 annual figure was -$540000.0, down 38.82% from the prior year.
- Cash from Investing Activities for Q2 2026 stood at -$238000.0, down from -$14000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $3000.0 in Q2 2024, with the low at -$760000.0 in Q2 2023.
- The 5-year median for Cash from Investing Activities is -$242000.0 (2025), against an average of -$326352.9.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities surged 100.39% in 2024, then slumped 8533.33% in 2025.
- Champions Oncology's Cash from Investing Activities stood at -$604000.0 in 2022, then jumped by 86.92% to -$79000.0 in 2023, then retreated by 18.99% to -$94000.0 in 2024, then plunged by 157.45% to -$242000.0 in 2025, then advanced by 1.65% to -$238000.0 in 2026.
- Business Quant data shows CSBR's Cash from Investing Activities at -$238000.0 in Q2 2026, -$14000.0 in Q1 2026, and -$242000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn | -238,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -238,000.00 |
| Apr 30, 2026 | -238,000.00 |
| Jan 31, 2026 | -14,000.00 |
| Jan 31, 2026 | -14,000.00 |
| Oct 31, 2025 | -242,000.00 |
| Oct 31, 2025 | -242,000.00 |
| Jul 31, 2025 | -46,000.00 |
| Jul 31, 2025 | -46,000.00 |
| Apr 30, 2025 | -253,000.00 |
| Apr 30, 2025 | -253,000.00 |
| Jan 31, 2025 | -42,000.00 |
| Jan 31, 2025 | -42,000.00 |
| Oct 31, 2024 | -94,000.00 |
| Oct 31, 2024 | -94,000.00 |
| Apr 30, 2024 | 3,000.00 |
| Apr 30, 2024 | 3,000.00 |
| Jan 31, 2024 | -92,000.00 |
| Jan 31, 2024 | -92,000.00 |
| Oct 31, 2023 | -79,000.00 |
| Oct 31, 2023 | -79,000.00 |